Compare Regeneron Pharmaceuticals Inc (REGN) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Western Alliance Bancorporation trades at $83.06 (market cap $8.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.1× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| REGN | WAL | |
|---|---|---|
Market Cap | $70.79B | $8.79B |
Sector | Health | Financials |
52-Week High | $812.27 | $96.08 |
52-Week Low | $545.46 | $66.70 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.43 and net income margin of 25.63%, supported by consistent quarterly earnings outperformance. Recent news highlights Q2 2026 earnings miss but positive corporate recognition and leadership appointments.
Outlook remains positive with analyst consensus price target of $90.67 suggesting 12% upside. Risks include negative operating cash flow and high interest expenses. The bullish analyst sentiment (79% buy ratings) contrasts with technical bearishness, indicating potential value opportunity if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
